What question did this study set out to answer?

To identify soluble members of the mesothelin and megakaryocyte potentiating factor family and evaluate their utility as circulating biomarkers for ovarian carcinoma.

September 28, 1999Proceedings of the National Academy of SciencesOpen Access

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

View Full Paper

Ask AI

Bookmark

Authors

NSNathalie SchollerAtara Biotherapeutics (United States)YYYi YangArmy Medical University ZYZhengmao YeGenentech

Discussion

Member takes

Implication

Diagnostic development study reveals elevated soluble mesothelin-related antigen in ovarian cancer sera, indicating its biomarker potential.

Key Points

To identify soluble members of the mesothelin and megakaryocyte potentiating factor family and evaluate their utility as circulating biomarkers for ovarian carcinoma.
Generated monoclonal antibody OV569 by immunizing mice with ovarian carcinoma cells and characterized its binding specificity against tumor cells, normal tissues, and mesothelin/MPF fusion proteins.
Identified a novel soluble variant of the mesothelin/MPF family featuring an 82-bp insert and a 212-bp frameshift in the membrane-associated domain.
Developed a two-epitope sandwich ELISA using OV569 and newly generated monoclonal antibodies to measure circulating antigen in sera from patients with ovarian carcinoma, other tumors, nonneoplastic conditions, and healthy controls.
Circulating antigen levels were significantly elevated in 23 of 30 sera from patients with ovarian carcinoma.
Elevated antigen was detected in 0 of 68 healthy controls, 0 of 3 nonneoplastic disease controls, and 25 of 75 sera from patients with other carcinomas.

Cite This Study

Scholler et al. (1999) studied this question.

synapsesocial.com/papers/6a8406e1356b31aeb3f2ef68 https://doi.org/10.1073/pnas.96.20.11531

View Full Paper

Ask AI

Bookmark

Implication

Diagnostic development study reveals elevated soluble mesothelin-related antigen in ovarian cancer sera, indicating its biomarker potential.

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider